Osteopore Discussion, page-4

I have no idea what is going on with OSX, but today's market cap is only 3.2M.

I was quite happy chipping in to the spp, which apparently raised 2.9M


ASX ANNOUNCEMENT
7 May 2024Osteopore successfully raises A$2.9m fromEntitlement OfferSingapore-founded regenerative medicine company Osteopore Limited (ASX:OSX orthe Company) – a global leader in 3D-printed biomimetic and bioresorbable implantsis pleased to announce the successful completion of its Renounceable Pro-RataEntitlement Offer and Shortfall Offer to raise ~A$3,000,000 (before costs)(Entitlement Offer) which closed on 2 April 2024.The Entitlement Offer provided eligible shareholders with the opportunity to subscribefor ten (10) fully paid ordinary shares (New Shares) for every one (1) fully paid ordinaryshare held (Shares) on the (Record Date) – at an issue price of A$0.029 per New Share– with one (1) free-attaching new option for every five (5) New Shares subscribed for,exercisable at A$0.0387 each and expiring 2 April 2026. (New Options).Under the Entitlement Offer, eligible shareholders were allowed to subscribe foradditional shares (Shortfall Offer). Applications for the Shortfall Offer closed on 2April 2024.Further to withdrawal rights expiring on 6 May 2024, the Company was delighted toraise approximately A$2,860,160 (before costs), representing a 95% take up rate bythe eligible shareholders. Under the Entitlement Offer, eligible shareholderssubscribed for 49,581,234 New Shares and 9,916,250 free-attaching New Options.Under the Shortfall Offer, eligible shareholders subscribed for 49,044,910 New Sharesand 9,809,023 free-attaching New Options.The issuance of New Shares and New Options under the Entitlement Offer and theShortfall Offer will occur on 8 May 2024, with normal trading of the New Sharesexpected to commence on 9 May 2024. The New Shares will rank equally with existingordinary shares on issue.The Company entered into a mandate with Advance Capital Partners Pte Ltd (AdvanceCapital) in connection with fund raising and general corporate advisory activities (theMandate). In connection with the Mandate, Advance Capital will be entitled to a fee of3% of the subscription amount from the Entitlement Offer.Funds raised via the Entitlement Offer will strengthen Osteopore’s balance sheet andmaintain sales momentum while supporting the Company to develop breakthroughproducts, secure market approvals, acquire complementary technologies, exploremergers and acquisition (M&A) opportunities and increase working capital.Osteopore continues to work towards developing the optimal conditions for revenuegrowth, whilst exploring different ways to improve the performance of our costcentres and streamline our expenses, with the effects of this starting to kick in overQ1 CY 2024.In Q1 CY24, the Company achieved its 5th straight quarter of uninterrupted revenuegrowth, which saw revenues peak at 76% Year-on-Year (YoY) and 15% Quarter-on-Quarter (QoQ). 1The Company wishes to thank its shareholders who participated in the EntitlementOffer for their ongoing commitment and dedication to Osteopore.